- Home
- CNF vs ALGS Comparison
CNF vs ALGS Comparison
Compare CNF & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNF
- ALGS
- Stock Information
- Founded
- CNF 1999
- ALGS 2018
- Country
- CNF China
- ALGS United States
- Employees
- CNF N/A
- ALGS N/A
- Industry
- CNF Finance: Consumer Services
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- CNF Finance
- ALGS Health Care
- Exchange
- CNF Nasdaq
- ALGS Nasdaq
- Market Cap
- CNF 36.9M
- ALGS 36.0M
- IPO Year
- CNF 2018
- ALGS 2020
- Fundamental
- Price
- CNF $0.42
- ALGS $5.40
- Analyst Decision
- CNF
- ALGS Strong Buy
- Analyst Count
- CNF 0
- ALGS 1
- Target Price
- CNF N/A
- ALGS $70.00
- AVG Volume (30 Days)
- CNF 125.0K
- ALGS 163.7K
- Earning Date
- CNF 04-30-2025
- ALGS 05-06-2025
- Dividend Yield
- CNF N/A
- ALGS N/A
- EPS Growth
- CNF N/A
- ALGS N/A
- EPS
- CNF 0.08
- ALGS N/A
- Revenue
- CNF $85,661,735.00
- ALGS $3,270,000.00
- Revenue This Year
- CNF $252.34
- ALGS N/A
- Revenue Next Year
- CNF N/A
- ALGS N/A
- P/E Ratio
- CNF $5.32
- ALGS N/A
- Revenue Growth
- CNF N/A
- ALGS N/A
- 52 Week Low
- CNF $0.37
- ALGS $3.76
- 52 Week High
- CNF $2.84
- ALGS $46.80
- Technical
- Relative Strength Index (RSI)
- CNF 21.74
- ALGS 43.34
- Support Level
- CNF $0.65
- ALGS $5.12
- Resistance Level
- CNF $0.75
- ALGS $6.12
- Average True Range (ATR)
- CNF 0.06
- ALGS 0.54
- MACD
- CNF -0.03
- ALGS 0.09
- Stochastic Oscillator
- CNF 7.89
- ALGS 13.53
About CNF CNFinance Holdings Limited each representing twenty (20)
CNFinance Holdings Ltd is an equity loan service provider. It focuses on the development of small and micro-enterprises. It generates revenue in the form of interest and financing service fees on loans and interest on deposits with banks. Its primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. Geographically, it has an operation in PRC.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.